Stockreport

Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors

HEMISPHERX BIOPHARMA  (HEB) 
NASDAQ:AMEX Investor Relations: hemispherx.net/mobile/investor-relations.php
PDF MIAMI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced that Pawel Kalinski, MD, vice ch [Read more]